Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M09D1 in Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
NCT07837622Phase 2Not yet recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M09D1 in urothelial carcinoma (UC), solid tumor, sponsored by Biokin Pharmaceutical. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
BL-M09D1
03
Conditions
urothelial carcinoma (UC)solid tumor
Beyond the preview
Go deeper on NCT07837622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07837622.